Takeda Pharmaceutical said today it has agreed to acquire stem cell therapy developer TiGenix for up to €520 million ($632 million) in a deal designed to strengthen the buyer’s late-stage gastroenterology pipeline and presence in the U.S. specialty care market.

The deal builds upon a partnership by the companies, through which TiGenix sold to Takeda ex-U.S. licensing rights to develop and commercialize Cx601 (darvadstrocel), an up-to-€390 million deal signed in July 2016 .

Cx601 is a suspension of allogeneic expanded adipose-derived stem cells. Last month, Cx601 became the first allogenic stem cell therapy to receive a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). That recommendation is expected to be the basis for a marketing authorization by the European Commission that is expected in the first half of this year.

Cx601 is expected to be indicated as a treatment …